Publications & Posters

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

All years

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of a variety of solid tumors

Ellwanger et al.
CIMT 2015

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells

Reusch et al.
MAbs. 2015 May 4;7(3):584-604. doi: 10.1080/19420862.2015.1029216. [PubMed - in process].

link to publication

In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs

Eissenberg et al.
ASCO 2015

Development Of A Bispecific Tetravalent CD33/CD3 TandAb For The Treatment of AML

Reusch et al.
ASCO 2015

Construction and Characterization of Novel CD33/CD3 Tandem Diabodies (TandAbs®) for the Treatment of Acute Myeloid Leukemia (AML)

Reusch et al.
ASCO 2015

TandAbs: potent and well-manufacturable bi-specific antibodies

Weichel et al.
European Pharmaceutical Review 2015 20(1): 27-32

link to publication

Specific NK cell activation to treat relapsed/refractory (r/r) Hodgkin Lymphoma (HL) patients – final, updated data on clinical outcome, pharmacokinetics and pharmacodynamics of a phase 1 study investigating AFM13, a bispecific anti- CD30/CD16A TandAb

Rothe et al.
ASH 2014

A CD19/CD3 bispecific TandAb, AFM11, recruits T cells to potently and safely kill CD19+ tumor cells in pre-clinical models

Reusch et al.
PEGS 2014

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.

Reusch et al.
MAbs. 2014 Mar 26;6(3).

link to publication

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients

Reiners et al.
Mol Ther. 2013 Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5./.

link to publication

1
2
3
4
5
6